TNF and infection: Although there has been no consensus on the risk of infections associated with anti-TNFα treatments in published clinical trials, post-marketing surveillance has shown an increase in the risk of tuberculosis and other granulomatous infections (Keane et al., 2001; Wallis et al., 2004).